BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 36547230)

  • 1. GATA3 Encapsulated by Tumor-Associated Macrophage-Derived Extracellular Vesicles Promotes Immune Escape and Chemotherapy Resistance of Ovarian Cancer Cells by Upregulating the CD24/Siglec-10 Axis.
    Chen C; Zhang L; Ruan Z
    Mol Pharm; 2023 Feb; 20(2):971-986. PubMed ID: 36547230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extracellular vesicles derived from M2-polarized tumor-associated macrophages promote immune escape in ovarian cancer through NEAT1/miR-101-3p/ZEB1/PD-L1 axis.
    Yin L; Wang Y
    Cancer Immunol Immunother; 2023 Mar; 72(3):743-758. PubMed ID: 36319716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delivery of SIRT1 by cancer-associated adipocyte-derived extracellular vesicles regulates immune response and tumorigenesis of ovarian cancer cells.
    Zheng Q; Du X; Zhang J; Liu Y; Dong W; Dai X; Gu D
    Clin Transl Oncol; 2024 Jan; 26(1):190-203. PubMed ID: 37311988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The biological roles of CD24 in ovarian cancer: old story, but new tales.
    Gu Y; Zhou G; Tang X; Shen F; Ding J; Hua K
    Front Immunol; 2023; 14():1183285. PubMed ID: 37359556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LncRNA IL21-AS1 facilitates tumour progression by enhancing CD24-induced phagocytosis inhibition and tumorigenesis in ovarian cancer.
    Liu J; Yan C; Xu S
    Cell Death Dis; 2024 May; 15(5):313. PubMed ID: 38702326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy.
    Barkal AA; Brewer RE; Markovic M; Kowarsky M; Barkal SA; Zaro BW; Krishnan V; Hatakeyama J; Dorigo O; Barkal LJ; Weissman IL
    Nature; 2019 Aug; 572(7769):392-396. PubMed ID: 31367043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TAM-derived extracellular vesicles containing microRNA-29a-3p explain the deterioration of ovarian cancer.
    Lu L; Ling W; Ruan Z
    Mol Ther Nucleic Acids; 2021 Sep; 25():468-482. PubMed ID: 34589270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GATA3 as a master regulator for interactions of tumor-associated macrophages with high-grade serous ovarian carcinoma.
    El-Arabey AA; Denizli M; Kanlikilicer P; Bayraktar R; Ivan C; Rashed M; Kabil N; Ozpolat B; Calin GA; Salama SA; Abd-Allah AR; Sood AK; Lopez-Berestein G
    Cell Signal; 2020 Apr; 68():109539. PubMed ID: 31935430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD24-Siglec axis is an innate immune checkpoint against metaflammation and metabolic disorder.
    Wang X; Liu M; Zhang J; Brown NK; Zhang P; Zhang Y; Liu H; Du X; Wu W; Devenport M; Tao W; Mao-Draayer Y; Chen GY; Chen YE; Zheng P; Liu Y
    Cell Metab; 2022 Aug; 34(8):1088-1103.e6. PubMed ID: 35921817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of a novel dual-targeting D-peptide to block CD24/Siglec-10 and PD-1/PD-L1 interaction and synergize with radiotherapy for cancer immunotherapy.
    Shen W; Shi P; Dong Q; Zhou X; Chen C; Sui X; Tian W; Zhu X; Wang X; Jin S; Wu Y; Chen G; Qiu L; Zhai W; Gao Y
    J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37344099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Siglec-G-CD24 axis controls the severity of graft-versus-host disease in mice.
    Toubai T; Hou G; Mathewson N; Liu C; Wang Y; Oravecz-Wilson K; Cummings E; Rossi C; Evers R; Sun Y; Wu J; Choi SW; Fang D; Zheng P; Liu Y; Reddy P
    Blood; 2014 May; 123(22):3512-23. PubMed ID: 24695850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. miR-106a-5p carried by tumor-derived extracellular vesicles promotes the invasion and metastasis of ovarian cancer by targeting KLF6.
    Zheng Y; Zhu K; Wang G
    Clin Exp Metastasis; 2022 Aug; 39(4):603-621. PubMed ID: 35449340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Whole-cell tumor vaccines desialylated to uncover tumor antigenic Gal/GalNAc epitopes elicit anti-tumor immunity.
    Huang J; Li M; Mei B; Li J; Zhu Y; Guo Q; Huang J; Zhang G
    J Transl Med; 2022 Oct; 20(1):496. PubMed ID: 36316782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel insights into the function of CD24: A driving force in cancer.
    Altevogt P; Sammar M; Hüser L; Kristiansen G
    Int J Cancer; 2021 Feb; 148(3):546-559. PubMed ID: 32790899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kynurenine in IDO1
    Ying X; Zheng X; Zhang X; Yin Y; Wang X
    J Transl Med; 2024 Mar; 22(1):267. PubMed ID: 38468343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting CD24/Siglec-10 signal pathway for cancer immunotherapy: recent advances and future directions.
    Li X; Tian W; Jiang Z; Song Y; Leng X; Yu J
    Cancer Immunol Immunother; 2024 Jan; 73(2):31. PubMed ID: 38279998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extracellular vesicle-packaged miR-181c-5p from epithelial ovarian cancer cells promotes M2 polarization of tumor-associated macrophages via the KAT2B/HOXA10 axis.
    Yang S; Zhao H; Xiao W; Shao L; Zhao C; Sun P
    J Gene Med; 2022 Oct; 24(10):e3446. PubMed ID: 36027869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Malignant ascite-derived extracellular vesicles inhibit T cell activity by upregulating Siglec-10 expression.
    Li Y; Zhou J; Zhuo Q; Zhang J; Xie J; Han S; Zhao S
    Cancer Manag Res; 2019; 11():7123-7134. PubMed ID: 31534365
    [No Abstract]   [Full Text] [Related]  

  • 19. Siglec-9
    Wang Y; He M; Zhang C; Cao K; Zhang G; Yang M; Huang Y; Jiang W; Liu H
    J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37709296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of CD24 and Siglec-10 in first trimester placenta: implications for immune tolerance at the fetal-maternal interface.
    Sammar M; Siwetz M; Meiri H; Fleming V; Altevogt P; Huppertz B
    Histochem Cell Biol; 2017 May; 147(5):565-574. PubMed ID: 28012129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.